Report
MaaT Pharma FIRST LOOK: DSMB green light de-risks MaaT013 phase 3 data in mid-2024
MaaT announced the outcome of the DSMB review for the phase 3 (ARES) trial of MaaT013 in aGvHD recommending the trial continue without modification, citing a favourable benefit/risk ratio. In our view the absence of safety concerns and preliminary efficacy (gastrointestinal overall response rate, GI-ORR) higher then pre-defined protocol assumptions provide comfort, de-risking the pivotal readout on the primary endpoint (GI-ORR) expected in mid-2024 – read our readout preview HERE. We reiterate our BUY rating and € 15 TP.
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.